Telaprevir Trial Boasts 80% Hepatitis C Cure Rate
Recent data from a Phase II trial claims that twice daily dosing of telaprevir cured Hepatitis C in over 80 participants.
Vertex Hep C Drug Cures 80% at New Dose: Study
10/31/09
By Adam Feuerstein
BOSTON (TheStreet) -- More than 80% of hepatitis C patients were cured after treatment with a new twice-daily dose of the experimental drug telaprevir made by Vertex Pharmaceuticals(VRTX Quote), according to data from a phase II study released Saturday.
Data from the new study demonstrates that a more convenient twice-daily dose of telaprevir is just as effective and safe as the thrice-daily dose, Vertex said.
Read the entire article:
http://www.thestreet.com/story/10619851/1/vertex-hep-c-drug-cures-80-at-new-dose-study.html?cm_ven=GOOGLEN